Now a cholesterol pill to cut down the risk of a heart attack?
|
A Monash University trial revealed that Obicetrapib
significantly lowered LDL cholesterol by 32.6% and lipoprotein(a) by 33.5% in
participants already on maximum tolerated doses of traditional therapies. |